NEW YORK (GenomeWeb News) – Sangamo BioSciences and Sigma-Aldrich said today that Roche has licensed Sangamo’s zinc finger nuclease technology to develop cell lines and transgenic animals that have targeted modifications in specific genes.
 
Zinc finger nucleases are engineered forms of zinc finger DNA-binding proteins that can be used to help modify target genes in organisms. Sigma-Aldrich is the exclusive licensee of Sangamo’s ZFN technology for research reagents.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.